Replies to post #1267 on GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

>a presence on the BOD and consequent veto power
No such power results from a board seat. The board votes
and the majority rules.

[Spice is nice]

You bring up some very good points, Tino

Although my initial intent was to vote no simply because I didn't trust the child around the cookie jar, after reading LFB's website I believe I am becoming more objecting of GTC being controlled by a nonprofit French agency. And let us not joust with the word "controlled". If GTC will roll over for anybody willing to give them a few million they appear certain to roll over for a governmental entity.

The more I look at this the more it stinks

using GTC’s transgenic production platform. A Joint Steering Committee will agree on product development as well as commercialization plans

I pray Y3maxx is not correct and instead it was a capitalist accumulating shares, preparing now to act as a white knight.

[alia]

Dear all, for fear of repeating some points made already, the French deal not only confers some measure of acceptance for GTCB's technology, the French company's experience and political connections might confer an advantage in getting Atryn etc. reimbursed which is crucial for the price which Atryn etc. will be able to command in the (state regulated, in the US as well as in Europe...) health care market. The same goes for Leo, which incidentally, is Danish, not Dutch.